1988 Agent Summary Statement for Human Immunodeficiency Virus and Report on Laboratory-Acquired Infection with Human Immunodeficiency Virus [MMWR, Vol 37 No.S-4]

22

MMWR

April 1, 1988

seroconversion. Results should be reported to individual workers in a timely
manner. Counseling services should be available for workers who have positive
serologic results. Procedures that maintain strict confidentiality should be
adopted.
F. Revalidate integrity of process, transport, and containment equipment
The operational integrity of all equipment used to process, transport, and
contain fluids containing HIV should be revalidated at least once a year. The
integrity of such equipment should be revalidated after any system failure that
releases contaminated fluids into the work environment.
G. Develop production processes that enhance biosafety
Efforts should be made to explore and use production systems and strategies
that reduce operational complexity and manual manipulations.
H. Validate efficacy of decontamination methods
Special attention should be given to demonstrating the adequacy of decontamination methods when high organic content, such as cellular debris, is
present.
I. Sponsor and conduct biosafety training initiatives
Responsible institutions should orient such programs toward the application
of biosafety practices to work involving HIV. Presentation strategies and
materials to make the training widely available should be encouraged.
References
1. CDC. Human T-lymphotropic virus type III/lymphadenopathy-associated virus: agent summary statement. MMWR 1986;35:540-2, 547-9.
2. Weiss SH, Goedert JJ, Gartner S, et al. Risk of human immunodeficiency virus (HIV-1)
infection among laboratory workers. Science 1988;239:68-71.
3. CDC. Recommendations for prevention of HIV transmission in health-care settings. MMWR
1987;36(suppl 2S):3S-18S.
19645

- ' ~~~ ~ ~ ~r '1 96-61O98O S